Puma Biotechnology (PBYI) relies on one product. It has weak fundamentals and has struggled to grow sales. PBYI stock has surged 91% over the past year, driven by technical momentum and speculative trading spikes. Despite technical “Buy” signals, analyst sentiment is mixed, with most rating PBYI as “Hold” or “Sell.” With stagnant revenue, declining earnings, and only one product, PBYI lacks compelling long-term investment appeal. Today’s Featured Stock Valued at $303 million, Puma Biotechnology ...